amantadine sulphate
ApprovedSmall molecule
amantadine sulphate is one of 46 small molecule programs targeting Hepatitis C. It is currently in Approved.
2
Indications
3
Total Trials
0
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
306 competitors in Hepatitis C
#DrugCompanyPhaseTrials
1Zepatier
Merck & Co.Phase 3
Lexapro
AbbViePhase 3
Victrelis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Pegylated Interferon
Merck & Co.Phase 3
Gocovri
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
Zetia
OOrganon and Co
Phase 3
Ombitasvir/paritaprevir/ritonavir
AbbViePhase 3
ABT-333
AbbViePhase 3
Grazoprevir/elbasvir
Merck & Co.Phase 3
Ledipasvir
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Amantadine1 trial
Benefits of Amantadine in Patients With Coma State
Unknown status·—··NCT03443037·56 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for amantadine sulphate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SSheba Medical Center